As of June 09, 2026, Enliven Therapeutics's top three insider holders are Advisors Llc Orbimed (Director, 8.66Mn shares), Advisors Llc Orbimed (Director, 7.66Mn shares), Partners Vi, Llc 5Am (TenPercentOwner, 4.31Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Advisors Llc Orbimed | - | 0 | 8,663,349 | 19 May, 2023 |
| David M Mott | - | 229,224 | 0 | 23 Feb, 2022 |
| Michael Gray | Cfo Coo | 27,610 | 0 | 22 Feb, 2023 |
| Capital Management, L.P. Ra | - | 0 | 2,122,465 | 27 Feb, 2023 |
| Braden Michael Leonard | - | 0 | 1,767,774 | 05 Jan, 2023 |
| Kenneth Attie | Svp, Cmo | 34,100 | 0 | 01 Feb, 2022 |
| Enterprise Associates 14, L.P. New | - | 2,611,050 | 0 | 07 Apr, 2022 |
| David P Bonita | - | 0 | 4,199,068 | 23 Jul, 2021 |
| Richard A. Heyman | - | 123,673 | 0 | 22 Oct, 2024 |
| Andrew J. Schwab | - | 0 | 960,383 | 27 Feb, 2023 |
| Jake Bauer | - | 87,372 | 0 | 27 Feb, 2023 |
| Helen Louise Collins | Chief Medical Officer | 25,000 | 0 | 21 Apr, 2026 |
| Mark Chin | - | 0 | 2,344,072 | 27 Jul, 2021 |
| Rahul D. Ballal | Chief Executive Officer | 22,341 | 0 | 10 Oct, 2024 |
| Partners Vi, Llc 5Am | - | 0 | 4,306,179 | 28 Sep, 2023 |
| Capital Lp Commodore | - | 0 | 1,448,640 | 27 Feb, 2023 |
| Benjamin Hohl | Chief Financial Officer | 51,000 | 0 | 10 Mar, 2026 |
| Joseph P Lyssikatos | Chief Scientific Officer | 0 | 740,188 | 10 Feb, 2026 |
| Anish Patel | Chief Operating Officer | 0 | 215,011 | 13 Jan, 2026 |
| Samuel Kintz | President And Ceo | 0 | 890,392 | 19 Nov, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Apr, 2026 | Helen Louise Collins | Common Stock | A | 5,000 | $2.48 | 30,000 | D | M |
| 17 Apr, 2026 | Helen Louise Collins | Common Stock | D | 140 | $45.81 | 29,860 | D | S |
| 17 Apr, 2026 | Helen Louise Collins | Common Stock | D | 2,419 | $47.39 | 27,441 | D | S |
| 17 Apr, 2026 | Helen Louise Collins | Common Stock | D | 2,441 | $48.06 | 25,000 | D | S |
| 17 Apr, 2026 | Helen Louise Collins | Stock Option (right to buy) | D | 5,000 | $0.00 | 131,268 | D | M |
| 25 Mar, 2026 | Helen Louise Collins | Common Stock | A | 40,000 | $2.48 | 65,000 | D | M |
| 25 Mar, 2026 | Helen Louise Collins | Common Stock | D | 40,000 | $35.10 | 25,000 | D | S |
| 25 Mar, 2026 | Helen Louise Collins | Stock Option (right to buy) | D | 40,000 | $0.00 | 136,268 | D | M |
| 17 Mar, 2026 | Helen Louise Collins | Common Stock | A | 5,000 | $2.48 | 30,000 | D | M |
| 17 Mar, 2026 | Helen Louise Collins | Common Stock | D | 5,000 | $27.76 | 25,000 | D | S |
| 17 Mar, 2026 | Helen Louise Collins | Stock Option (right to buy) | D | 5,000 | $0.00 | 176,268 | D | M |
| 09 Mar, 2026 | Helen Louise Collins | Common Stock | A | 29,871 | $2.48 | 54,871 | D | M |
| 09 Mar, 2026 | Helen Louise Collins | Common Stock | D | 29,871 | $30.02 | 25,000 | D | S |
| 10 Mar, 2026 | Helen Louise Collins | Common Stock | A | 10,129 | $2.48 | 35,129 | D | M |
| 10 Mar, 2026 | Helen Louise Collins | Common Stock | D | 10,129 | $30.19 | 25,000 | D | S |
| 09 Mar, 2026 | Helen Louise Collins | Stock Option (right to buy) | D | 29,871 | $0.00 | 191,397 | D | M |
| 10 Mar, 2026 | Helen Louise Collins | Stock Option (right to buy) | D | 10,129 | $0.00 | 181,268 | D | M |
| 06 Mar, 2026 | Benjamin Hohl | Common Stock | D | 10,000 | $29.58 | 51,000 | D | S |
| 06 Mar, 2026 | Benjamin Hohl | Common Stock | D | 10,000 | $29.58 | 51,000 | D | S |
| 06 Mar, 2026 | Benjamin Hohl | Common Stock | D | 10,000 | $29.58 | 51,000 | D | S |